Fig. 5From: Migraine treatment: quo vadis? Real-world data study (2015–2022) in SpainPercentage of migraine patients prescribed with anti-calcitonin gene-related peptide monoclonal antibodies per number of previous acute and preventive treatments received between January 2015 and April 2022 (Cohort F)Back to article page